Status of chloroquine efficacy against falciparum malaria in the Mola area of Kariba district, Zimbabwe

S. Mharakurwa, R. Rangarira, F. C. Murahwa, S. K. Chandiwana

Research output: Contribution to journalArticle

Abstract

The therapeutic efficacy of chloroquine was assessed, during the 1997 transmission season, using 64 cases of uncomplicated, falciparum malaria originating from 18 villages in the Mola area of Kariba district, Zimbabwe. Chloroquine effected a modest reduction in asexual parasite density and clinical symptoms. The mean density of asexual parasites on day 3 post-treatment was 24.94% (95% confidence interval = 13.59%-36.30%) of that on day 0, and 78% of the patients followed-up for at least 1 week were free of parasitaemia on day 7. However, there was appreciable therapeutic failure. The early treatment failure rate (i.e. by day 3) was 21% and about 6% of the cases exhibited increasing asexual parasitaemia despite treatment. Late treatment failures (i.e. by day 14) occurred in 32% of the malaria cases, and 52% of the patients were ultimately considered failures. All the failures were successfully treated with sulfadoxine-pyrimethamine or quinine. Chloroquine therefore has declining parasitological and clinical value as the first-line, presumptive treatment for uncomplicated, falciparum malaria in the study area, necessitating strategies to cope with resistant cases. The proportion of the patients failing to be treated successfully with chloroquine, one of the largest reported in Zimbabwe to date, may force major policy reviews in the near future. It is recommended that the second-line antimalarial, sulfadokine-pyrimethamine, be distributed to health-centre level in the study area, backed up by the decentralised confirmation of diagnosis. Measures to deal with treatment failures at local health centres are proposed.

Original languageEnglish (US)
Pages (from-to)655-661
Number of pages7
JournalAnnals of Tropical Medicine and Parasitology
Volume92
Issue number6
DOIs
StatePublished - 1998
Externally publishedYes

Fingerprint

Zimbabwe
Falciparum Malaria
Chloroquine
Treatment Failure
Parasitemia
Parasites
Therapeutics
Pyrimethamine
Quinine
Antimalarials
Health Status
Malaria
Confidence Intervals
Health

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases
  • Immunology

Cite this

Status of chloroquine efficacy against falciparum malaria in the Mola area of Kariba district, Zimbabwe. / Mharakurwa, S.; Rangarira, R.; Murahwa, F. C.; Chandiwana, S. K.

In: Annals of Tropical Medicine and Parasitology, Vol. 92, No. 6, 1998, p. 655-661.

Research output: Contribution to journalArticle

Mharakurwa, S. ; Rangarira, R. ; Murahwa, F. C. ; Chandiwana, S. K. / Status of chloroquine efficacy against falciparum malaria in the Mola area of Kariba district, Zimbabwe. In: Annals of Tropical Medicine and Parasitology. 1998 ; Vol. 92, No. 6. pp. 655-661.
@article{559a64f0843641b8be6430fc96814136,
title = "Status of chloroquine efficacy against falciparum malaria in the Mola area of Kariba district, Zimbabwe",
abstract = "The therapeutic efficacy of chloroquine was assessed, during the 1997 transmission season, using 64 cases of uncomplicated, falciparum malaria originating from 18 villages in the Mola area of Kariba district, Zimbabwe. Chloroquine effected a modest reduction in asexual parasite density and clinical symptoms. The mean density of asexual parasites on day 3 post-treatment was 24.94{\%} (95{\%} confidence interval = 13.59{\%}-36.30{\%}) of that on day 0, and 78{\%} of the patients followed-up for at least 1 week were free of parasitaemia on day 7. However, there was appreciable therapeutic failure. The early treatment failure rate (i.e. by day 3) was 21{\%} and about 6{\%} of the cases exhibited increasing asexual parasitaemia despite treatment. Late treatment failures (i.e. by day 14) occurred in 32{\%} of the malaria cases, and 52{\%} of the patients were ultimately considered failures. All the failures were successfully treated with sulfadoxine-pyrimethamine or quinine. Chloroquine therefore has declining parasitological and clinical value as the first-line, presumptive treatment for uncomplicated, falciparum malaria in the study area, necessitating strategies to cope with resistant cases. The proportion of the patients failing to be treated successfully with chloroquine, one of the largest reported in Zimbabwe to date, may force major policy reviews in the near future. It is recommended that the second-line antimalarial, sulfadokine-pyrimethamine, be distributed to health-centre level in the study area, backed up by the decentralised confirmation of diagnosis. Measures to deal with treatment failures at local health centres are proposed.",
author = "S. Mharakurwa and R. Rangarira and Murahwa, {F. C.} and Chandiwana, {S. K.}",
year = "1998",
doi = "10.1080/00034989859113",
language = "English (US)",
volume = "92",
pages = "655--661",
journal = "Pathogens and Global Health",
issn = "2047-7724",
publisher = "Maney Publishing",
number = "6",

}

TY - JOUR

T1 - Status of chloroquine efficacy against falciparum malaria in the Mola area of Kariba district, Zimbabwe

AU - Mharakurwa, S.

AU - Rangarira, R.

AU - Murahwa, F. C.

AU - Chandiwana, S. K.

PY - 1998

Y1 - 1998

N2 - The therapeutic efficacy of chloroquine was assessed, during the 1997 transmission season, using 64 cases of uncomplicated, falciparum malaria originating from 18 villages in the Mola area of Kariba district, Zimbabwe. Chloroquine effected a modest reduction in asexual parasite density and clinical symptoms. The mean density of asexual parasites on day 3 post-treatment was 24.94% (95% confidence interval = 13.59%-36.30%) of that on day 0, and 78% of the patients followed-up for at least 1 week were free of parasitaemia on day 7. However, there was appreciable therapeutic failure. The early treatment failure rate (i.e. by day 3) was 21% and about 6% of the cases exhibited increasing asexual parasitaemia despite treatment. Late treatment failures (i.e. by day 14) occurred in 32% of the malaria cases, and 52% of the patients were ultimately considered failures. All the failures were successfully treated with sulfadoxine-pyrimethamine or quinine. Chloroquine therefore has declining parasitological and clinical value as the first-line, presumptive treatment for uncomplicated, falciparum malaria in the study area, necessitating strategies to cope with resistant cases. The proportion of the patients failing to be treated successfully with chloroquine, one of the largest reported in Zimbabwe to date, may force major policy reviews in the near future. It is recommended that the second-line antimalarial, sulfadokine-pyrimethamine, be distributed to health-centre level in the study area, backed up by the decentralised confirmation of diagnosis. Measures to deal with treatment failures at local health centres are proposed.

AB - The therapeutic efficacy of chloroquine was assessed, during the 1997 transmission season, using 64 cases of uncomplicated, falciparum malaria originating from 18 villages in the Mola area of Kariba district, Zimbabwe. Chloroquine effected a modest reduction in asexual parasite density and clinical symptoms. The mean density of asexual parasites on day 3 post-treatment was 24.94% (95% confidence interval = 13.59%-36.30%) of that on day 0, and 78% of the patients followed-up for at least 1 week were free of parasitaemia on day 7. However, there was appreciable therapeutic failure. The early treatment failure rate (i.e. by day 3) was 21% and about 6% of the cases exhibited increasing asexual parasitaemia despite treatment. Late treatment failures (i.e. by day 14) occurred in 32% of the malaria cases, and 52% of the patients were ultimately considered failures. All the failures were successfully treated with sulfadoxine-pyrimethamine or quinine. Chloroquine therefore has declining parasitological and clinical value as the first-line, presumptive treatment for uncomplicated, falciparum malaria in the study area, necessitating strategies to cope with resistant cases. The proportion of the patients failing to be treated successfully with chloroquine, one of the largest reported in Zimbabwe to date, may force major policy reviews in the near future. It is recommended that the second-line antimalarial, sulfadokine-pyrimethamine, be distributed to health-centre level in the study area, backed up by the decentralised confirmation of diagnosis. Measures to deal with treatment failures at local health centres are proposed.

UR - http://www.scopus.com/inward/record.url?scp=0032321831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032321831&partnerID=8YFLogxK

U2 - 10.1080/00034989859113

DO - 10.1080/00034989859113

M3 - Article

C2 - 9924544

AN - SCOPUS:0032321831

VL - 92

SP - 655

EP - 661

JO - Pathogens and Global Health

JF - Pathogens and Global Health

SN - 2047-7724

IS - 6

ER -